Trialtrove: Clinical Trial Intelligence Guide

Trialtrove is a curated clinical trial intelligence platform developed and maintained by Citeline that aggregates, standardizes, and indexes interventional and observational study data from global trial registries, corporate disclosures, scientific congresses, and regulatory filings. Designed for clinical development sponsors, contract research organizations (CROs), and clinical operations teams, the platform provides structured metrics on study designs, primary endpoints, enrollment velocity, investigator site footprints, and competitive pipeline dynamics across human clinical investigations.

In clinical research administration, trial design and site feasibility assessments frequently encounter fragmented data across regional registries such as ClinicalTrials.gov, the EU Clinical Trials Information System (CTIS), the Japanese JAPIC registry, and the Chinese Clinical Trial Registry (ChiCTR). Trialtrove synthesizes these disparate records into unified trial profiles, linking protocol design elements with competitive landscape timelines and site-level historical performance. This enables clinical teams managing a clinical trial protocol to evaluate enrollment feasibility, optimize inclusion and exclusion criteria, and conduct data-driven clinical trial site selection before opening protocol recruitment.

What Trialtrove Is

Trialtrove is an enterprise clinical trial intelligence database and analytics environment that monitors the progression of clinical trials worldwide from early Phase I safety investigations through Phase IV post-marketing surveillance. Rather than functioning simply as a public registry aggregator, the platform utilizes manual curation by subject-matter scientific analysts who validate trial characteristics, harmonize varied medical terminologies, resolve multi-registry duplicates, and track amendments to protocol milestones over time.

The platform operates within Citeline’s broader clinical and commercial intelligence suite, connecting trial protocol records directly with Sitetrove (investigator and clinical site historical metrics) and Pharmaprojects (global drug development pipeline tracking from preclinical discovery to approval). Within pharmaceutical development and CRO oversight frameworks, such as those governed by sponsor oversight under ICH E6(R3), Trialtrove serves as a primary decision-support system during protocol concept development, competitive feasibility benchmarking, and vendor allocation assessments.

Who Runs It and What It Covers

Trialtrove is owned and operated by Citeline, a life sciences commercial intelligence organization operating under parent company Norstella (having previously operated under Informa Pharma Intelligence). The platform’s coverage and dataset include:

• Trial Volume: Encompasses more than 555,000 clinical trial records spanning past, active, planned, and terminated human studies worldwide.
• Therapeutic Breadth: Indexes clinical investigations across more than 350 disease indications and medical conditions, categorizing trials by therapeutic area, biomarker targets, mechanism of action, and intervention modality.
• Data Sources: Continuously monitors and extracts data from over 70,000 global sources, including public government registries (such as ClinicalTrials.gov, WHO ICTRP, EudraCT/CTIS, ChiCTR, and JAPIC), medical congress presentations, peer-reviewed scientific journals, company quarterly earnings announcements, and investor disclosures.
• Update Frequency: Maintained on a daily update cycle, incorporating newly disclosed protocols, investigator site activations, trial status modifications, and trial result disclosures as they become public.

Core Features and Analytics Modules

Trialtrove structures complex clinical trial data into dedicated analytical modules designed to support cross-functional trial planning, clinical operations, and competitive intelligence teams:

• Study Activity Analytics: Visualizes historical and active clinical development timelines, plotting phase duration, regulatory milestone intervals, and protocol amendment patterns to help sponsors establish realistic development timelines.
• Enrollment Analytics: Benchmarks patient recruitment velocity and accrual performance by country, therapeutic indication, and trial phase. This allows feasibility teams to identify patient recruitment bottlenecks and calculate realistic recruitment run rates.
• Competitive Landscape Mapping: Enables clinical development strategists to evaluate competing trials in the same indication, assessing sponsor pipeline saturation, overlapping eligibility criteria, and competing demands for the same target patient cohorts.
• Trends and Patient Competition: Tracks geographic trial density to highlight regional site crowding where multiple concurrent protocols compete for limited patient sub-populations.
• Ella AI Assistant: A conversational AI search and synthesis interface that allows users to construct complex protocol search queries, summarize trial design attributes, and retrieve comparative trial benchmarks using natural language.

How to Search and Use Trialtrove for Trial Feasibility

Conducting protocol benchmarking and site feasibility analysis within Trialtrove follows a structured workflow aligned with clinical trial planning standards:

1. Define Indication and Mechanism Parameters: Access the search console and establish the therapeutic area, specific disease classification, biomarker criteria, and molecular mechanism of action under investigation.
2. Filter Study Phase and Trial Status: Constrain queries by development phase (Phase I through Phase III/IV), trial status (ongoing, planned, or completed), and intervention type (small molecule, biologic, cell or gene therapy, or medical device).
3. Extract Protocol Design and Endpoint Standards: Review curated trial records to inspect primary and secondary endpoint definitions, control arms (placebo, standard of care, or active comparator), and blinding strategies adopted in successfully completed trials.
4. Analyze Eligibility and Exclusion Restrictiveness: Examine patient population parameters across competitor protocols to identify restrictive exclusion criteria that historically correlated with extended accrual delays or trial terminations.
5. Benchmark Enrollment Rates by Geography: Open the Enrollment Analytics dashboard to evaluate patient recruitment rates (patients per site per month) across candidate countries and clinical regions.
6. Evaluate Investigator and Site Overlap: Cross-reference candidate trial records with Sitetrove to identify clinical trial sites and qualified principal investigators who have demonstrated historical compliance, high accrual fidelity, and manageable competing protocol loads.
7. Export Standardized Datasets: Export curated trial lists and aggregated metric summaries into structured formats (CSV, Excel, or API feeds) for integration into clinical project management and governance reviews.

Strengths and Limitations

Evaluating Trialtrove requires understanding both its analytical strengths and operational limitations within academic and commercial research environments.

Platform Strengths

• Harmonized Global Data: By reconciling data from over 70,000 multi-lingual sources, Trialtrove eliminates the need for manual, error-prone cross-registry searching.
• Expert Scientific Curation: Analysts standardize protocol endpoints, drug mechanisms, and study outcomes, converting unstructured registry text into queryable quantitative parameters.
• Integrated Site and Drug Intelligence: Native connectivity to Sitetrove and Pharmaprojects links protocol data directly with site performance and drug pipeline status.
• Actionable Feasibility Metrics: Quantitative enrollment velocity benchmarks provide realistic timelines for budgeting and CRO contract negotiation, supporting decisions detailed in our clinical trial outsourcing decision framework and our comparison of sponsor vs CRO responsibilities.

Platform Limitations

• Proprietary Commercial Licensing: Unlike public clinical trial registries, Trialtrove requires an enterprise annual subscription, restricting access primarily to well-funded biopharmaceutical sponsors, large CROs, and major academic medical centers.
• Commercial and Regulatory Disclosure Lag: While public registries and news feeds are monitored daily, proprietary protocol modifications that sponsors are not legally required to publish immediately may experience minor reporting delays.
• Verification Requirements for Observational Cohorts: While interventional drug trials are comprehensively indexed, investigator-initiated observational studies and real-world evidence registries may exhibit varying degrees of historical completeness.

Alternatives to Trialtrove

Research organizations utilize diverse clinical trial information repositories depending on their research objectives, regulatory context, and budgetary resources. The table below compares Trialtrove with leading open-access and commercial clinical trial intelligence repositories:

Platform	Operator / Governance	Access Model	Primary Data Sources	Key Strengths
Trialtrove (Citeline)	Citeline (Norstella)	Proprietary commercial subscription	70,000+ sources: global registries, congresses, press releases, regulatory filings	Expert data curation, enrollment analytics, competitive benchmarking, integrated site metrics
ClinicalTrials.gov	U.S. National Library of Medicine (NLM / NIH)	Free public access	Sponsor and investigator mandatory submissions under FDAAA 801 and 42 CFR Part 11	Primary statutory registry for U.S.-regulated trials, official protocol results database
WHO ICTRP	World Health Organization	Free public access	Primary registries in the WHO Registry Network (including ANZCTR, ChiCTR, CTRI, EudraCT/CTIS)	Global multi-registry aggregation, standardized 24-item trial dataset, international public health tracking
Cortellis Clinical Trials	Clarivate	Proprietary commercial subscription	Global trial registries, regulatory portals, scientific literature, conference abstracts	Regulatory intelligence integration, biomarker profiling, intellectual property and patent linkage
EU CTIS / EudraCT	European Medicines Agency (EMA)	Free public access (portal)	Mandatory clinical trial authorization applications across European Union member states	Official legal record for clinical trials conducted in the EU/EEA under Regulation (EU) No 536/2014

For independent researchers and academic teams reviewing scientific literature and publication standards, our guide to peer review standards in scientific journals provides further context on evaluating published clinical research data.

Frequently Asked Questions

What is Citeline Trialtrove?

Citeline Trialtrove is a comprehensive, curated clinical trials intelligence platform that aggregates data from global registries, regulatory disclosures, and scientific conferences to provide benchmarking on clinical trial designs, endpoints, enrollment timelines, and competitive landscapes.

How does Trialtrove differ from ClinicalTrials.gov?

ClinicalTrials.gov is a free public registry maintained by the U.S. National Library of Medicine where trial sponsors submit legally mandated protocol disclosures under U.S. federal law. In contrast, Trialtrove is a commercial intelligence suite that aggregates ClinicalTrials.gov alongside dozens of other international registries, curates and normalizes unstructured trial data, and provides quantitative enrollment velocity benchmarks and competitive pipeline analytics.

Who uses Trialtrove in clinical research?

Trialtrove is utilized by clinical operations teams, protocol designers, medical directors, CRO feasibility managers, and competitive intelligence professionals at biopharmaceutical companies, contract research organizations, and academic medical centers.

Can Trialtrove be integrated with other clinical data systems?

Yes. Trialtrove integrates natively with Citeline’s Sitetrove (investigator site data) and Pharmaprojects (drug pipeline data). In addition, enterprise organizations can integrate Trialtrove intelligence into internal data warehouses and clinical trial management systems (CTMS) via REST API feeds and scheduled data exports.

Sources

• Citeline. “Trialtrove+: The Industry’s Most Comprehensive Clinical Trial Intelligence.” Citeline Product Documentation, 2026. Read November 7, 2026. https://www.citeline.com/en/solutions/trialtrove
• Frontiers in Oncology. “Global clinical trial activity in metastatic castration-resistant prostate cancer: a landscape analysis.” Frontiers in Oncology, PMC13662642, 2026. Read November 7, 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662642/
• Stem Cells Translational Medicine. “Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape.” Stem Cells Translational Medicine, PMC13726808, 2026. Read November 7, 2026. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13726808/